| ALK TKIs in real-world patients were found highly tolerable with only 24.8%, 17.9%, and 6.0% of patients experiencing an AE requiring treatment dose adjustment, interruption, or discontinuation, respectively. |
| Our findings of longer survival outcomes of mAEFS, rwPFS, and OS highlighted the higher tolerability and effectiveness of alectinib compared with crizotinib. |
| Proactive monitoring for adverse events such as rash, bradycardia, and hepatotoxicity may help further promote the safe and optimal use of ALK TKIs in the treatment of patients with aNSCLC. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.